Exome sequencing of the TCL1 mouse model for CLL reveals genetic heterogeneity and dynamics during disease development.
Nadja ZaborskyFranz J GassnerJan P HöpnerMaria SchubertDaniel HebenstreitRichard StarkDaniela AsslaberMarkus SteinerRoland GeisbergerRichard GreilAlexander EglePublished in: Leukemia (2018)
The TCL1 mouse model is widely used to study pathophysiology, clonal evolution, and drug sensitivity or resistance of chronic lymphocytic leukemia (CLL). By performing whole exome sequencing, we present the genetic landscape of primary tumors from TCL1 mice and of TCL1 tumors serially transplanted into wild-type recipients to mimic clonal evolution. We show that similar to CLL patients, mutations in mice are frequently subclonal and heterogenous among different primary TCL1 mice. We further describe that this molecular heterogeneity mirrors heterogenous disease characteristics such as organ infiltration or CLL dependent T cell skewing. Similar to human CLL, we further observed the occurrence of novel mutations and structural variations during clonal evolution and found plasticity in the expansion of B cell receptor specific subclones. Thus, our results uncover that the genetic complexity, pathway dependence and clonal dynamics in mouse CLL are in relevant agreement to human CLL, and they are important to consider in future research using the TCL1 mouse for studying CLL.
Keyphrases
- chronic lymphocytic leukemia
- mouse model
- wild type
- single cell
- endothelial cells
- high fat diet induced
- genome wide
- copy number
- newly diagnosed
- ejection fraction
- end stage renal disease
- type diabetes
- metabolic syndrome
- risk assessment
- skeletal muscle
- prognostic factors
- adipose tissue
- gene expression
- pluripotent stem cells
- current status
- patient reported outcomes
- binding protein
- drug induced